Serial #99211010
LIVE

Serial Number

99211010

Owner

Avidity Biosciences, Inc.

Attorney

Aaron D. Hendelman

Filing Date

May 30, 2025

Add to watchlist:

No watchlists yet
View on USPTO

Serial #99211010 Trademark

Serial Number: 99211010

Serial #99211010 is a trademark filed by Avidity Biosciences, Inc. on May 30, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Avidity Biosciences, Inc. (41 trademarks)

10578 Science Drive, Suite 125
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

May 30, 2025

Registration Date

Not Registered

Published for Opposition

September 16, 2025

Goods & Services

Providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceuticals, therapeutics, medicines, and vaccines, and medical information in the fields of healthcare, health conditions, health awareness and treatment options; medical information services, namely, providing information related to healthcare, diseases, disorders, and treatment options; online medical information services, namely, providing a website related to healthcare, health awareness, diseases, disorders, treatment options, and the diagnostic, prophylactic and therapeutic properties of medicines and vaccines

Custom manufacturing of oligonucleotide-conjugate based pharmaceutical therapies, oligonucleotide-antibody conjugate based pharmaceutical therapies, and oligonucleotide-antibody fragment conjugate based pharmaceutical therapies; custom manufacturing of pharmaceuticals; contract manufacturing in the field of pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing

Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology; providing medical and scientific research information in the fields of pharmaceuticals, therapeutics, medicines and vaccines

Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 26, 2026 EXRA
SOU EXTENSION 1 GRANTED
Mar 25, 2026 EX1G
SOU EXTENSION 1 FILED
Mar 25, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 25, 2026 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 5, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 5, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 5, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 5, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 5, 2026 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 16, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 16, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 10, 2025 NONP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 5, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 5, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 5, 2025 COAR
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 15, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 15, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 15, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 15, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 12, 2025 GNRN
NON-FINAL ACTION E-MAILED
Aug 12, 2025 GNRT
NON-FINAL ACTION WRITTEN
Aug 12, 2025 CNRT
ASSIGNED TO EXAMINER
Aug 6, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jul 29, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 29, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
May 30, 2025 MAFR
NEW APPLICATION ENTERED
May 30, 2025 NWAP